Riskpilot← Back to searchSign inGet full accessSavacc AB
ABActiveOrg 5590055918Ollonstigen 3Manufacture of pharmaceutical preparations · NACE 2120Est. 20150 employees
Revenue 2024
SEK 0
EBITDA margin
—
+37% vs 2023
Equity ratio
88.6%
Financial strength
Net profit 2024
SEK -4K
0 employees
| Revenue | SEK 0 | — |
| EBITDA | SEK -27K | +37% |
| Net profit | SEK -4K | — |
| Total assets | SEK 1M | -3% |
| Equity | SEK 914K | +0% |
| Employees | 0 | — |
Legal name
Savacc AB
Org number
5590055918
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
2 mars 2015
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva vaccinutveckling och därmed jömförlig verksamhet inom bioteknik samt därmed förenlig verksamhet.
Address
Ollonstigen 3
Email
bror.morein@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 240 | 240 | 156 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −19 | 113 | −28 | −42 | −27 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −19 | 113 | −28 | −42 | −27 |
| Net financials | — | −2 | — | — | 0 |
| Profit before tax | 6 | 83 | 1 | 2 | −4 |
| Tax | −6 | −18 | −1 | −2 | — |
| Net profit | 0 | 65 | 0 | 0 | −4 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 968 | 1 068 | 1 424 | 1 059 | 1 032 |
| Equity | 424 | 489 | 918 | 918 | 914 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 405 | 412 | 367 | 46 | 45 |
| Total debt | 405 | 412 | 367 | 46 | 45 |
EBITDA margin
-2654500.0%
This company
15.8%
Market median
-16800733% vs market
20202024
Equity ratio
88.6%
This company
38.2%
Market median
+132% vs market
20202024
Return on equity
-0.4%
This company
18.4%
Market median
-102% vs market
20202024
Net profit margin
-365500.0%
This company
8.1%
Market median
-4512446% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EI Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Iscovent Aktiebolag
Savacc AB Board members of Savacc AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ella Ingegerd Morein | Chief Executive Officer | 0 companies |
| Bror Gunnar Vilhelm Morein | Chairman | 0 companies |
| Carl Gunnar Torbjörn Morein | Deputy Board Member | 0 companies |